source
- BridgeBio Oncology shares tumble 24% as it narrows KRAS program focusBridgeBio Oncology Therapeutics saw its stock drop sharply after announcing a strategic shift. The company said it will scale back its broader pipeline to concentrate resources on its lead KRAS in…
- Takeda R&D chief Andy Plump to retire after string of recent FDA approvalsTakeda's long-serving research and development president Andy Plump will step down in June. He joined the Japanese drugmaker in 2015 from Sanofi and has led the R&D organization since then. His ex…